AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

Brazil
Brazil will locally produce Oxford's shot at the Oswaldo Cruz Foundation, also known as Fiocruz. (Pixabay)

In an effort to supercharge distribution of its vaccine hopeful, British drugmaker AstraZeneca has spanned the globe to ink a slew of national supply deals. Now, after striking a more limited pact in June, AstraZeneca and Brazil are ramping up their partnership to make even more doses of the shot.

Brazilian President Jair Bolsonaro ordered $360 million set aside last week for a supply and licensing deal with AstraZeneca for at least 100 million doses of the University of Oxford's adenovirus-based COVID-19 vaccine.

Those funds will cover the initial 100 million-dose order, AstraZeneca said, as well as Brazil's licensing rights to produce the shot at the Oswaldo Cruz Foundation, also known as Fiocruz, if the vaccine is found effective in clinical trials.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

An AstraZeneca spokesman said the new agreement "builds on" the drugmaker's earlier deal with Brazil in June to supply around 30 million unfinished doses of the vaccine at a price tag of $127 million.

RELATED: AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID-19 shot

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.